
    
      This study is a Phase 1 clinical trial comprised of two parts. In part one, 9 subjects are
      assigned to group A,B,C. Dose escalation is used in In group A with no non-myeloablative
      chemotherapy, group B and group C will undergo a non-myeloablative chemotherapy before the
      cell infusion. Whether the part 2 of the trial continue is determined by the result of part
      1. If continues, 15 subjects will be enrolled into the trial and receive a regimen of immune
      cell infusion combined with non-myeloablative chemotherapy.
    
  